Why BioRestorative Therapies Stock Is Moving Higher Thursday

6/13/24 11:52:46 AM ET

$BRTX

$CADL

Managed Health Care

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BRTX alert in real time by email

BioRestorative Therapies, Inc. (NASDAQ:BRTX) shares are trading higher Thursday after the company said it has engaged in licensing discussions with a undisclosed commercial regenerative medicine company.

What Happened: BioRestorative Therapies announced before the market opened on Thursday that it engaged in substantive licensing discussions with an regenerative medicine company related to its ThermoStem Metabolic Disease Program intellectual property.

Research conducted in collaboration with the University of Utah School of Medicine has demonstrated that certain stem cells with brown adipogenic potential could represent a new way of treating obesity and related metabolic disorders.

Currently, there is no guarantee that a license agreement will be made between the two companies.

Related Link: Candel Therapeutics’ (NASDAQ:CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

BRTX Price Action: At the time of writing, BioRestorative shares are trading 29% higher at $1.75 per data from Benzinga Pro.

Image: Image via Shutterstock

Get the next $BRTX alert in real time by email

Company	Date	Price Target	Rating	Analyst
Candel Therapeutics Inc. $CADL	12/2/2022	$11.00	Buy	H.C. Wainwright
BioRestorative Therapies Inc. $BRTX	12/1/2021	$37.00	Buy	Roth Capital
Candel Therapeutics Inc. $CADL	11/19/2021	$18.00	Outperform	BMO Capital
Candel Therapeutics Inc. $CADL	8/23/2021	$9.00	Buy	UBS
Candel Therapeutics Inc. $CADL	8/23/2021	$22.00	Buy	Jefferies
Candel Therapeutics Inc. $CADL	8/23/2021	$15.00	Outperform	Credit Suisse

Why BioRestorative Therapies Stock Is Moving Higher Thursday

Chat with this insight

Recent Analyst Ratings for $BRTX$CADL

$BRTX$CADL Press Releases

Fastest customizable press release news feed in the world

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data

BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

$BRTX$CADL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Silva Francisco bought $10,229 worth of shares (8,308 units at $1.23), increasing direct ownership by 6% to 155,759 units (SEC Form 4)

Broadrick Dale bought $206,023 worth of shares (160,000 units at $1.29) (SEC Form 4)

Broadrick Dale bought $162,255 worth of shares (120,000 units at $1.35), increasing direct ownership by 37% to 447,045 units (SEC Form 4)

$BRTX$CADL Financials

Live finance-specific insights

$BRTX$CADL Large Ownership Changes

This live feed shows all institutional transactions in real time.

BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data

BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium

SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

$BRTX$CADL Market Insights

Live Market Insights

GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing

BioRestorative Therapies Announces Notice Of Allowance For Patent Related To Its ThermoStem Platform

BioRestorative Therapies shares are trading higher after the company announced it regained compliance with the Nasdaq.

$BRTX$CADL SEC Filings

$BRTX$CADL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 10-Q filed by Candel Therapeutics Inc.

Candel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

BioRestorative Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Chief Executive Officer Tak Paul Peter exercised 12,900 shares at a strike of $1.55, increasing direct ownership by 4% to 343,635 units (SEC Form 4)

Large owner Aguilar-Cordova Estuardo returned $231,600 worth of CADL to the company (45,000 units at $5.15), decreasing direct ownership by 3% to 873,512 units (SEC Form 4)

Large owner Broadrick Dale sold $1,757 worth of shares (1,112 units at $1.58), decreasing direct ownership by 0.25% to 445,933 units (SEC Form 4)

$BRTX$CADL Leadership Updates

Live Leadership Updates

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Candel Therapeutics to Join Russell 3000® Index

Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors

$BRTX$CADL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Candel Therapeutics with a new price target

Roth Capital initiated coverage on BioRestorative Therapies with a new price target

BMO Capital initiated coverage on Candel Therapeutics with a new price target

Recent Analyst Ratings for
$BRTX
$CADL

$BRTX
$CADL
Press Releases

$BRTX
$CADL
Insider Purchases

$BRTX
$CADL
Financials

$BRTX
$CADL
Large Ownership Changes

$BRTX
$CADL
Market Insights

$BRTX
$CADL
SEC Filings

$BRTX
$CADL
Insider Trading

$BRTX
$CADL
Leadership Updates

$BRTX
$CADL
Analyst Ratings